Familial Hypercholesterolemia in Spain: Case-Finding Program, Clinical and Genetic Aspects

A case-finding program for the identification of patients with familial hypercholesterolemia (FH) has been established in Spain. The program is based on family investigation and molecular genetic testing for mutations in the low-density lipoprotein receptor gene. To assist this program, intensive research into the molecular basis of FH and genotype/phenotype relations is performed. To optimize DNA testing, a DNA-diagnostic platform has been constructed that is composed of systematic mutation screening by single-strand conformation polymorphism (SSCP) analysis, DNA-sequencing, Southern blotting, and the use of microarrays for high-throughput analysis. To date, 161 different mutations leading to inherited hypercholesterolemia have been identified in Spanish patients with FH. In addition, a patient organization was founded to ensure patient support and follow-up. To further facilitate FH case-finding and patient follow-up, we initiated the publication of a set of guidelines for diagnosis and clinical management of FH that can be applied internationally.

KEYWORDS

Familial hypercholesterolemia - genetics - low-density lipoprotein receptor - mutation - case-finding - microarray

REFERENCES

• 1 Goldstein J L, Hobbs H H, Brown M S. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D The Metabolic and Molecular Basis of Inherited Disease. New York; McGraw-Hill 2001: 2863-2913
• 2 Williams R, Hunt S, Schumacher C et al.. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics.  Am J Cardiol. 1993;  72 171-176
• 3 Defesche J. Familial Hypercholesterolemia. In: Betteridge J Lipids and Vascular Disease. London; Martin Dunitz 2000 6: 65-76
• 4 Umans-Eckenhausen M AW, Defesche J C, Sijbrands E JG, Scheerder R LJM, Kastelein J JP. Review of first 5 years of screening for familial hypercholesterolaemia in The Netherlands.  Lancet. 2001;  357 165-168
• 5 Williams R R, Schumacher M C, Barlow G K et al.. Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah.  Am J Cardiol. 1993;  72 18D-24D
• 6 World Health Organization .Human Genetics Program. Familial Hypercholesterolemia, a Global Perspective. WHO/HGN/FH/CONS/99.2 Geneva; World Health Organization 1999
• 7 Alonso R, Castillo S, Civeira F et al.. Hipercolesterolemia familiar heterocigota en España. Estudio descriptivo de 819 casos no relacionados.  Med Clin. 2002;  118 487-492
• 8 Alonso-Villaverde C, Sardá P, Vallvé J C et al.. Manifestaciones clínicas de la hipercolesterolemia familiar en una población mediterránea.  Med Clin (Barc). 1999;  113 521-525
• 9 Garcés C, Rodríguez-Artalejo F, Serrano A et al.. Manifestaciones clínicas de la hipercolesterolemia familiar heterocigota en España. Estudio de 301 casos de la zona centro y norte.  Med Clin (Barc). 2000;  114 50-51
• 10 Cenarro A, Jensen H K, Civeira F et al.. Two novel mutations in the LDL receptor gene: common causes of familial hypercholesterolemia in Spain.  Clin Genet. 1996;  49 180-185
• 11 Cenarro A, Jensen H K, Casao E et al.. Identification of a novel mutation in exon 13 of the LDL receptor gene causing familial hypercholesterolemia in two Spanish families.  Biochim Biophys Acta. 1996;  1316 1-4
• 12 Cenarro A, Jensen H K, Casao E et al.. Identification of recurrent and novel mutations in the LDL receptor gene in Spanish patients with familial hypercholesterolemia.  Hum Mutat. 1998;  11 413
• 13 Mozas P, Cenarro A, Civeira F, Castillo S, Ros E, Pocovi M. Mutation analysis in 36 unrelated Spanish subjects with familial hypercholesterolemia: identification of 3 novel mutations in the LDL receptor gene.  Hum Mutat. 2000;  15 483-484
• 14 Vallve J C, Alonso-Villaverde C, Ribalta J, Perez-Jimenez F, Masana L. Exon 4, and in particular codon 152 of the LDL receptor gene, is a hot spot for point mutations.  Atherosclerosis. 1998;  140 191-192
• 15 Chaves F J, Real J T, Garcia-Garcia A B et al.. Large rearrangements of the LDL receptor gene and profile in a FH Spanish population.  Eur J Clin Invest. 2001;  31 309-317
• 16 Garcia-Garcia A B, Real J T, Puig O et al.. Molecular genetics of familial hypercholesterolemia in Spain: ten novel LDLR mutations and population analysis.  Hum Mutat. 2001;  18 458-459
• 17 Fischer E, Scharnagi H, Hoffmann M M et al.. Mutation in the apolipoprotein (apo) B-100 receptor-binding region: detection of apoB-100 (Arg3500->Trp) associated with two new haplotypes and evidence that apoB-100 (Glu 3405->Gln) disminishes receptor-mediated uptake of LDL.  Clin Chem. 1999;  45 1026-1038
• 18 Real J T, Chaves J F, Ascaso J F et al.. Familial defect of apo B-100 in subjects with clinically diagnosed primary hypercholesterolemia: identification of the first family with this disorder in Spain [in Spanish].  Med Clin (Barc). 1999;  113 15-17
• 19 Ejarque I, Civera M, Ascaso J F et al.. Identification and characterization of the first Spanish familial-defective apolipoprotein B homozygote.  Med Clin (Barc). 2001;  116 138-141
• 20 Castillo S, Tejedor D, Mozas P et al.. The apolipoprotein B R3500Q gene mutation in Spanish subjects with a clinical diagnosis of familial hipercolesterolemia.  Atherosclerosis. 2002;  165 127-135
• 21 Cronin M T, Fucini R V, Kim S M, Masino R S, Wespi R M, Miyada C G. Cystic fibrosis mutation detection by hybridization to light-generated DNA probe arrays.  Hum Mutat. 1996;  7 244-255
• 22 Hacia J G, Brody L C, Chee M S, Fodor S P, Collins F S. Detection of heterozygous mutations in BRCA1 using high-density oligonucleotide arrays and two-colour fluorescence analysis.  Nat Genet. 1996;  14 441-447
• 23 Henegariu O, Heerema N A, Dlouhy S R, Vance G H, Vogt P H. Multiplex PCR: Critical Parameters and Step-by-Step Protocol.  Biotechniques. 1997;  23 504-511
• 24 Syvänen A C. Accesing genetic variation: genotyping single nucleotide polymorphisms.  Nat Rev Genet. 2001;  2 930-942
• 25 Heath K E, Day I NM, Humphries S E. Universal primer quantitative fluorescent Multiplex (UPQFM) PCR: a method to detect major and minor rearrangements of the low density lipoprotein receptor gene.  J Med Genet. 2000;  37 272-280
• 26 Nichos P, Young I S, Graham C A. Phenotype/phenotype correlations in familial hypercholesterolaemia.  Curr Opin Lipidol. 1998;  9 313-317
• 27 Jansen A CM, van Wissen S, Defesche J C, Kastelein J JP. Phenotypic variability in familial hypercholesterolemia: an update.  Curr Opin Lipidol. 2002;  13 165-171
• 28 Wilson P W, Schaefer E J, Larson M G, Ordovas J M. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis.  Arterioscler Thromb Vasc Biol. 1996;  16 1250-1255
• 29 Eto M, Watanabe K, Chonan N, Ishii K. Familial hypercholesterolemia and apolipoprotein E4.  Atherosclerosis. 1988;  72 123-128
• 30 Kitahara M, Shinomiya M, Shirai K, Saito Y, Yoshida S. Frequency and role of apo E phenotype in familial hypercholesterolemia and non-familial hyperlipidemia in the Japanese.  Atherosclerosis. 1990;  82 197-204
• 31 Hill J S, Hayden M R, Frohlich J, Pritchard P H. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia.  Arterioscler Thromb. 1991;  11 290-297
• 32 Ferrières J, Sing C F, Roy M, Davignon J, Lussier-Cacan S. Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia. Sex-specific effects.  Arterioscler Thromb. 1994;  14 1553-1560
• 33 Lindahl G, Mailly F, Humphries S, Seed M. Apolipoprotein E phenotype and lipoprotein(a) in familial hypercholesterolaemia: implication for lipoprotein(a) metabolism.  Clin Investig. 1994;  72 631-638
• 34 Tonstad S, Leren T P, Sivertsen M, Ose L. Determinants of lipid levels among children with heterozygous familial hypercholesterolemia in Norway.  Arterioscler Thromb Vasc Biol. 1995;  15 1009-1014
• 35 Carmena-Ramon R, Real J T, Ascaso J F, Ordovas J M, Carmena R. Effect of apolipoprotein E genotype on lipid levels and response to diet in familial hypercholesterolemia.  Nutr Metab Cardiovasc Dis. 2000;  10 7-13
• 36 Bertolini S, Cantafora A, Averna M et al.. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype.  Arterioscler Thromb Vasc Biol. 2000;  20 E41-E52
• 37 Mozas P, Castillo S, Reyes G et al.. Apolipoprotein E genotype is not associated with cardiovascular disease in heterozygous subjects with Familial Hypercholesterolemia.  Am Heart J. 2003;  145 999-1005
• 38 Clee S M, Zwinderman A H, Engert J C et al.. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease.  Circulation. 2001;  103 1198-1205
• 39 Lutucuta S, Ballantyne C M, Elghannam H, Gotto Jr A M, Marian A J. Novel polymorphisms in promoter region of ATP binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy.  Circ Res. 2001;  88 969-973
• 40 Cenarro A, Artienda M, Castillo S et al.. A common variant in the ABCA1 gene is associated with lower risk for premature coronary heart disease in familial hypercholesterolemia.  J Med Genet. 2003;  40 163-168
• 41 International Panel of Management of Familial Hypercholesterolemia .Guidelines for the management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004 In press